Diffuse Alopecia Areata

    January 2018
    Pooya Khan Mohammad Beigi
    TLDR Diffuse alopecia areata causes widespread hair thinning due to an autoimmune response.
    Diffuse alopecia areata (AA) was identified as a distinct form of alopecia areata characterized by widespread scalp hair thinning rather than the typical patchy hair loss. It was a non-scarring condition that posed diagnostic challenges. The pathophysiology was not fully understood, but it was thought to involve an autoimmune response targeting anagen stage hair follicles, potentially affecting melanocytes, dermal papilla cells, and keratinocytes. Diffuse AA was noted for its intense inflammation and rapid progression compared to patchy AA, with inflammatory infiltrates including mononuclear cells, eosinophils, CD3+ T cells, and CD8+ T cells.
    Discuss this study in the Community →

    Research cited in this study

    4 / 4 results

    Related Community Posts Join

    6 / 1000+ results

      community It’s over. NOTHING has worked.

      in Chat  95 upvotes 3 years ago
      A user who has been trying various treatments for hair loss for four years, with no success. Suggestions include use of minoxidil, finasteride, RU58841, microneedling, supplements and multivitamins, lifestyle changes, scalp biopsy, and SMP.

      community Hair loss over a year following depression and taking antidepressants

      in Side effects?  194 upvotes 4 days ago
      A 33-year-old experienced significant hair loss after a depressive episode and taking paroxetine, possibly due to telogen effluvium or androgenic alopecia. Suggestions included reducing alcohol, considering finasteride and minoxidil, and consulting a doctor about antidepressant side effects.

      community HLT Megathread on HMI-115 (key takeaways in comments)

      in Research/Science  39 upvotes 2 years ago
      HMI-115, a newly discovered hair loss treatment that could potentially be effective for those with diffuse thinning and telogen effluvium. It is based on prolactin receptor antagonist signaling and has already undergone Phase I trials in women, with potential commercialization by 2027.

    Related Research

    3 / 3 results